# LTBI Reporting in Maryland

Alexandra Pyan, MPH

**Prevention and Health Promotion Administration** 

Center for Tuberculosis Control and Prevention

April 25, 2018



## Why LTBI, Why Now

- LTBI surveillance is key to TB elimination
- Majority of TB cases in Maryland are due to reactivation of LTBI
- US Preventive Health Service recommendations on screening for LTBI
- Adoption of national LTBI case definition
- Short course therapy
- Support of key stakeholders including LHDs




### What we'll learn

- Better understanding of burden of LTBI in Maryland
- Better understanding of who is screening and treating LTBI
- Identify gaps in both screening and treatment
- Identify populations for targeting outreach



### LTBI Cascade to Cure-



Alsdurf et al. The Cascade of Care of Latent TB Infection: A Systematic Review Lancet ID 2016



### LTBI Case Definition

- Confirmed LTBI Case
  - A positive tuberculin skin test (TST) **OR**
  - A positive interferon gamma release assay (IGRA) AND
  - Active disease has been ruled out
- Suspected LTBI Case
  - A positive tuberculin skin test (TST) **OR**
  - A positive interferon gamma release assay (IGRA)



# COMAR 10.06.01.03 Language

### Latent Tuberculosis Infection

- (a) A positive result on an Interferon Gamma Release Assay, or Tuberculin Skin Test, or any other test indicating TB infection, and
- (b) Active or suspected tuberculosis has been ruled out.

### **Active Tuberculosis**

- (a) A laboratory confirmed acid-fast bacillus on smear;
- (b) An abnormal chest radiograph suggestive of active tuberculosis;
- (c) A laboratory confirmed biopsy report consistent with active tuberculosis; or
- (d) Initiation of two or more anti-tuberculosis medications.



## What are we collecting?-

- Demographic information
- Reason for LTBI screening
- Risk factors
  - HIV, Diabetes, immune modulating drugs, congregate living
- Testing and evaluation
  - TST, IGRA, chest imaging, sputum smear and culture
- Treatment information
  - Treatment start, regimen, completion



#### Maryland Latent Tuberculosis Infection (LTBI) Reporting Form

						-			0.0		500			
Provider name:						32.00					*	BI case status		
Provider affiliation:							☐ Confirmed ☐ Suspected TB Infection ☐ Not LTBI case number (if known):							
Provider telephone	:					LII	BI case nu	ımber	(if know	vn): _				
			□ Ini	itial Repo	rt	□ Follo	w-up Rep	port						
Last name First name			Middle			1	Date of birth (MM/DD/YYY			YYYY	Y) Sex at birth  Male Unknown Female			
Address Unit #			# City or Town				State Zip code			le	County of residence			
Patient telephone	U.Sborn Coun			ntry of birth				Month/Year arrived in			in U.S.			
Race (select all that apply)  American Indian or Alaskan Native  Native Hawaiian/Other Pacific Islander		☐ Asian ☐ Black or Africa ☐ White ☐ Other Race				an-American			Ethnicity  ☐ Hispanic or Latino ☐ Unknown ☐ Not Hispanic or Latin				nic or Latino	
		Re	port	ing Info	rmat	ion an	d Risk	facto	rs					
Name of reporting	ng agency:			0			ate of firs			ation	:			
Reporting agency type select one					Rea	son for	LTBI tes	st selec	ct one					
☐ Employment ☐ Long-term care fa					□ F	Healthcare worker				☐ Testing to rule out TB				
☐ Correctional facility ☐ Immigrant/refuge				2		School/e	ducation	screen	reening			oyment/administrative test		
☐ Military ☐ Private medical ca				vider	□ E	B-waiver				☐ Refugee screen (non B-waiver)				
☐ Local health dept. ☐ Federally qualified				h center		Contact investigation. Contact   Other:								
☐ School/daycar	e 🗆 Other:						if known:	:						
HIV status at diagnosis Risk facto					ors check all that apply									
☐ Negative						End-stage renal disease ☐ Congregate living situation  Homeless within past year ☐ Immune modulating drugs								
☐ Positive				moking										
□ Unknown							Injection drug user ☐ Pregnancy Non-injection drug use ☐ Other:							
				Testing				ig tist		inci.				
TST		IGRA		Testing	ganu	Lvare	ation	Sme	ar Col	lectio	n Dat	e:		
Agency:	Test date:								: Desitive Negative					
Date read:	Test type: □ QFT □ T-SPOT				()ther			☐ Unknown ☐ Not done						
Interpretation:						Ci			Culture Collection Date:					
☐ Positive	Interpreta		☐ Positi					Result Date: Negative						
☐ Negative	□ Unkno				Indeterminate			☐ Unknown ☐ Not done						
D	□ Not do		☐ Faile	ed/Inva	and			TB □ Not consistent with TB						
Date of chest rac other chest imag		Chest rad	_	•			onsistent Inknown	with I		Not do		nt with 1B		
Final evaluation				***	□ Act		RVCT ca	ice min						
111111111111111111111111111111111111111	outcome:					tment			noer (ii					
Was the patient										No				
Reason patient did not start LTBI treatment:						LTBI treatment regimen prescribed:								
☐ Refused ☐ Referred for treatm														
☐ Provider decision Referral:					□ 4 n	☐ 4 months Rifampin								
☐ Previous LTBI treatment					□ 12 weeks Isoniazid/Rifapentine									
☐ Previous TB treatment					☐ Other:									
☐ Lost to follow	1													
LTBI treatment	start date:						eatment s	toppe						
						nent con				regnar				
A TOV				(2.33			manufacture and an armine to the first of th			Provider decision				
LTBI treatment					Lost to care			☐ Patient moved						
				☐ Adverse ☐ Other:			event			ied				
Serious adverse	event/reaction t	o LTBI tre	atmer	nt: Hos	pitaliz	ation [	☐ Death ☐	Othe	er:			□ None	1	



## Who will report?

- Everyone!
- Local health departments, community clinics, private providers
- Anyone doing screening including schools, occupational health, prisons
- Laboratories



### How will it work?

- Effective April 23, 2018
- Official start date July 1, 2018
- CTBCP will receive all LTBI reports
  - Completed reports can be mailed/faxed to CTBCP
- New LTBI condition in NEDSS
- New LTBI data manager at CTBCP



### How will it work?

- LHD follow current procedures for referrals
- LHD report on all LTBI they screen or treat
  - Including contacts and B-waivers
- COMAR requires reporting with 1 working day of LTBI diagnosis
  - CTBCP will work with larger facilities on individual basis for batched reporting



### How will it work?

- CTBCP will no longer send positive IGRA to TST results to LHD
- ELR's
  - If a positive IGRA is reported for an active case or suspect it should be associated with appropriate TB case investigation in NEDSS
  - If LHD follows up on a positive IGRA report, a comment should be made on ELR noting the follow-up response. If active disease is ruled out, the LHD should then report the LTBI case.
  - The CTBCP will create a new LTBI suspect in NEDSS for all other positive IGRA results received through ELR.
- Evolving and changing process!



### How will we use the data?

- Looking at who is and is not be screened
- Treatment regimens utilized
- Treatment completion rates
- Partnering for outreach to high-risk populations



# **Questions?**





# Maryland Department of Health Prevention and Health Promotion Administration

https://phpa.health.maryland.gov

